Denali Therapeutics (DNLI)

Denali Therapeutics (DNLI) Financial Statements


Denali Therapeutics Financial Overview

Denali Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.588; its P/E ratio is -8.85; Denali Therapeutics is scheduled to report earnings on November 2, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 10.28M$ 3.56M$ 52.48M$ 42.14M$ 12.51M
Gross Profit-----
EBIT$ -105.34M$ -107.49M$ -61.42M$ -66.50M$ -77.12M
EBITDA$ -101.25M$ -105.34M$ -59.34M$ -64.42M$ -75.03M
Net Income Common Stockholders$ -98.68M$ -103.30M$ -58.79M$ -65.22M$ -75.26M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.34B$ 1.11B$ 1.07B$ 957.52M$ 865.41M
Total Assets$ 1.46B$ 1.23B$ 1.29B$ 1.32B$ 1.40B
Total Debt$ 60.35M$ 62.05M$ 61.40M$ 62.74M$ 64.01M
Net Debt$ -1.28B$ -1.04B$ -1.01B$ -894.78M$ -801.40M
Total Liabilities$ 417.81M$ 416.30M$ 408.01M$ 402.93M$ 441.87M
Stockholders Equity$ 1.04B$ 811.30M$ 884.45M$ 917.93M$ 962.29M
Cash Flow-
Free Cash Flow$ -77.51M$ -63.10M$ -45.79M$ -76.15M$ -68.55M
Operating Cash Flow$ -72.66M$ -57.05M$ -42.90M$ -72.11M$ -65.49M
Investing Cash Flow$ -127.56M$ 15.42M$ 88.63M$ -117.88M$ -40.75M
Financing Cash Flow$ 299.65M$ 5.15M$ 4.40M$ 1.46M$ 5.17M
Currency in USD

Denali Therapeutics Earnings and Revenue History

Denali Therapeutics Debt to Assets

Denali Therapeutics Cash Flow

Denali Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis